Article Text

Download PDFPDF
Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In Japanese patients with hypercholesterolaemia (HC), does long term use of eicosapentaenoic acid (EPA) reduce major coronary events?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Cardiology ★★★★★☆☆ Endocrine ★★★★★☆☆


Embedded ImageDesign:

randomised controlled trial (RCT) (Japan EPA Lipid Intervention Study [JELIS]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (outcome assessors, {data analysts, and data safety and monitoring committee}).*

Embedded ImageFollow up period:

mean 4.6 years.

Embedded ImageSetting:


Embedded ImagePatients:

18 645 patients 40–75 years of age (mean age 61 y, 69% postmenopausal women) from Japan with or without coronary artery disease (previous myocardial infarction [MI], coronary interventions, or angina pectoris) who had a total cholesterol concentration ⩾6.5 mmol/l (low density lipoprotein [LDL] cholesterol concentration ⩾4.4 mmol/l). Exclusion criteria included acute MI, cardiovascular (CV) reconstruction, or cerebrovascular disorders in …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: Dr M Yokoyama, Kobe University, Japan. yokoyama{at}

  • Source of funding: Mochida Pharmaceutical Co. Ltd.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd